BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 28496006)

  • 21. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Basement membrane-related gene signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy].
    Wang ZH; Liu Z; Zhao XD; Hu EY; Chen YH; Xu XF; Xia J; Liu YH; Dong J; Xu S; Cheng W
    Zhonghua Nan Ke Xue; 2022 Dec; 28(12):1071-1079. PubMed ID: 37846626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
    Heering M; Berg KD; Brasso K; Iversen P; Røder MA
    Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
    BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
    Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies.
    Cheng A; Zhao S; FitzGerald LM; Wright JL; Kolb S; Karnes RJ; Jenkins RB; Davicioni E; Ostrander EA; Feng Z; Fan JB; Dai JY; Stanford JL
    Prostate; 2019 Oct; 79(14):1589-1596. PubMed ID: 31376183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.
    Erho N; Crisan A; Vergara IA; Mitra AP; Ghadessi M; Buerki C; Bergstralh EJ; Kollmeyer T; Fink S; Haddad Z; Zimmermann B; Sierocinski T; Ballman KV; Triche TJ; Black PC; Karnes RJ; Klee G; Davicioni E; Jenkins RB
    PLoS One; 2013; 8(6):e66855. PubMed ID: 23826159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
    Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
    Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.
    Shahabi A; Lewinger JP; Ren J; April C; Sherrod AE; Hacia JG; Daneshmand S; Gill I; Pinski JK; Fan JB; Stern MC
    Prostate; 2016 Oct; 76(14):1239-56. PubMed ID: 27272349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
    Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
    Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
    Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
    Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of Gleason score 3 + 4 = 7 prostate cancer with minimal amounts (<6%) vs ≥6% of Gleason pattern 4 tissue in needle biopsy specimens.
    Kır G; Seneldir H; Gumus E
    Ann Diagn Pathol; 2016 Feb; 20():48-51. PubMed ID: 26750655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification a novel set of 6 differential expressed genes in prostate cancer that can potentially predict biochemical recurrence after curative surgery.
    Li F; Ji JP; Xu Y; Liu RL
    Clin Transl Oncol; 2019 Aug; 21(8):1067-1075. PubMed ID: 30637711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.
    Magi-Galluzzi C; Maddala T; Falzarano SM; Cherbavaz DB; Zhang N; Knezevic D; Febbo PG; Lee M; Lawrence HJ; Klein EA
    Oncotarget; 2016 Jun; 7(23):33855-65. PubMed ID: 27121323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.